SCHEMBL6926155

SCHEMBL6926155

Nc1nc2c(NCCc3ccccn3)c(-c3cccc(Cl)c3)ccc2o1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 3/20 0.42
HSD17B10 Q99714 3/20 0.42
ADORA2A P29274 2/20 0.40
ADORA1 P30542 2/20 0.40
LMNA P02545 2/20 0.39
PKM P14618 1/20 0.39
AURKA O14965 1/20 0.37
CYP1A2 P05177 1/20 0.37
HIF1A Q16665 1/20 0.37
HPGD P15428 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
POLB P06746 1/20 0.36
APP P05067 2/20 0.36
PIK3CA P42336 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6931312 0.80 F2 (0.53) MEN1KMT2AL3MBTL1ADORA2AADORA1
SCHEMBL31301592 0.70 STK3 (0.69) RAB9AAURKASMN1; SMN2
SCHEMBL3705838 0.67 MAPT (0.48) MEN1KMT2AL3MBTL1NPC1RAB9A
SCHEMBL9093601 0.65 CYP1A2 (0.69) NPC1RAB9AKDM4EALDH1A1LMNA
SCHEMBL6795360 0.65 CNR1 (0.50) MEN1KMT2ANPC1RAB9AKDM4E
SCHEMBL6932736 0.64 F2 (0.63)
SCHEMBL13779425 0.64 HIF1A (0.46) MEN1KMT2AL3MBTL1NPC1RAB9A
SCHEMBL2918546 0.64 TDO2 (0.41) NPC1RAB9AADORA2AADORA1LMNA
SCHEMBL13779086 0.63 GBA1 (0.50) MEN1KMT2AADORA2AADORA1LMNA
SCHEMBL1947636 0.62 F2RL3 (0.50) NPC1RAB9AKDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225131-A1 Thrombin inhibitors BURGEY CHRISTOPHER S (US) 2003-12-04 US claimed
US-20030225131-A1 Thrombin inhibitors BURGEY CHRISTOPHER S (US) 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225131-A1 Thrombin inhibitors TFPI, SERPINC1, PLAT MEN1 1306/4885KMT2A 3473/4885L3MBTL1 3276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.